Nuwellis appoints Dr John Jefferies as CMO

Nuwellis, Inc., a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO). In this new role, Dr Jefferies will provide Nuwellis with strategic guidance on clinical and medical affairs issues, act as a liaison between the Company and the medical community and serve as a key advisor on corporate development matters.

“I am thrilled to welcome Dr Jefferies in this new role of CMO,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “Dr Jefferies’ pediatric training and expertise in cardiology and heart failure make him the ideal person for this role as we prepare to bring new products to market and continue expanding the body of clinical evidence supporting ultrafiltration.”

Dr Jefferies currently serves as the Jay M. Sullivan Endowed Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center. He will continue in this role while serving as CMO for Nuwellis. Dr Jefferies began his medical career with a combined residency in internal medicine and pediatrics at the University of Kentucky. Dr Jefferies then completed a fellowship in general internal medicine and earned a master’s degree in public health from the University of Kentucky before completing an additional combined fellowship in adult cardiovascular diseases and pediatric cardiology at the Baylor College of Medicine. He has authored or co-authored more than 250 peer-reviewed manuscripts, functioned as lead editor for two textbooks, and sits on the editorial boards of several journals. Dr Jefferies has served on the Nuwellis medical advisory board since 2019.

“It’s an exciting time to be working with Nuwellis,” said Dr Jefferies. “I’ve seen firsthand how the company’s Aquadex therapy can make a real difference for heart failure patients. I’m eager to put my expertise to work to bring new technology to market and expand the clinical data surrounding ultrafiltration, with the ultimate goal of providing better outcomes for more patients in the future.”
MB Bureau